Every 10-Q that Actuate Therapeutics, Inc. (ACTU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACTU filings page.
Actuate Therapeutics reported a net loss of $4.9 million for the quarter and $10.5 million for the six months ended June 30 2026, narrowing losses versus 2025 as research and development and general and administrative expenses both declined.
Cash and cash equivalents were $4.4 million with working capital of $0.94 million, and management estimates existing cash will not fund operations beyond September 2026 without additional capital, leading to a stated substantial doubt about continuing as a going concern. The company has an unused capacity of about $98.7 million under its at-the-market equity facility and a separate Committed Equity Facility.
Operationally, Actuate advanced its lead GSK‑3β inhibitor elraglusib. An oral tablet IND was cleared by the FDA for a Phase 1/2 study in advanced cancers, following Phase 2 IV results in first-line metastatic pancreatic cancer that showed improved median overall survival and higher 12‑ and 24‑month survival rates versus control. The company also agreed to evaluate elraglusib in the BEACON2 pediatric neuroblastoma platform study.
Actuate Therapeutics reports a Q1 2026 net loss of $5,625,749, modestly improved from $6,317,024 a year earlier, as it advances lead cancer drug elraglusib. Research and development expenses were $2,565,244 and general and administrative costs were $3,140,712, both roughly stable to slightly lower year over year.
Cash and cash equivalents were $8,134,004 with working capital of $3,797,551, and management expects this to fund operations only into July 2026, leading to a conclusion of substantial doubt about continuing as a going concern. The company is relying on a $100M at-the-market facility and a separate $50M committed equity facility for future funding.
Clinically, updated Phase 2 data in metastatic pancreatic cancer showed median overall survival of 10.1 months for elraglusib plus standard therapy versus 7.2 months for control, with higher 12- and 24-month survival rates, supporting plans for an oral formulation and additional studies, subject to securing more capital.
Actuate Therapeutics filed its Q3 2025 10‑Q, reporting a net loss of $5.41 million for the quarter and $17.67 million for the nine months ended September 30, 2025. Operating expenses were $5.47 million in Q3, with research and development $2.18 million and general and administrative $3.29 million.
Cash and cash equivalents were $16.92 million as of September 30, 2025; working capital was $11.07 million. Management stated there is “substantial doubt” about the company’s ability to continue as a going concern and projects its current cash will not fund operations beyond the second quarter of fiscal 2026 without additional capital.
Actuate raised capital through multiple transactions: an underwritten public offering of 2,464,286 shares at $7.00 per share for net proceeds of $15.57 million, a June 2025 private placement yielding $4.59 million, and sales under a Committed Equity Facility with B. Riley providing net proceeds of $3.80 million during the period. Shares outstanding were 23,243,328 as of November 12, 2025.